5-Amino-1MQ Capsule is synthesized from ortho aminobenzoic acid through cyclization reaction to form 6-methylquinoline-2,4 (1H, 3H) - dione (yield 85%). It introduces amino groups through nitrification reduction reaction, followed by nucleophilic substitution with methyl iodide (yield 78%). In the C2C12 muscle cell model, treatment with 5-Amino-1MQ can increase mitochondrial membrane potential, and JC-1 staining showed a 25% increase in membrane potential, reflecting improvement in mitochondrial function. It can also increase ATP production. Seahorse XF analysis showed an 18% increase in ATP production, indicating an improvement in energy metabolism efficiency. This substance reduces reactive oxygen species (ROS) levels, and DCFH-DA probe detection shows a 30% decrease in ROS levels, alleviating oxidative stress damage.
We not only provide pure powder and capsules, but also other dosage forms. If necessary, please contact our sales team.
Our products from









5-Amino-1MQ COA



5-Amino-1MQ Capsule is a selective nicotinamide N-methyltransferase (NNMT) inhibitor with great potential in metabolic research and obesity treatment. It inhibits NNMT activity, reduces the conversion of nicotinamide to 1-methylnicotinamide, increases intracellular NAD ⁺ levels, enhances mitochondrial energy metabolism efficiency, and promotes fat breakdown and energy expenditure.
Basic properties and mechanism of action of 5-Amino-1MQ
5-Amino-1MQ (5-amino-1-methylquinolinium, CAS number: 42464-96-0) is a small molecule compound with the molecular formula C ₁₀ H ₁₁ N ₂ ⁺ and a molecular weight of 183.21 g/mol. Its chemical structure consists of a quinoline ring, an amino group (- NH ₂), and a methyl group (- CH ∝), where the methyl group forms a quaternary ammonium salt structure with the nitrogen atom of the quinoline ring. In terms of physical properties, 5-Amino-1MQ usually exists in the form of white to light yellow crystalline powder, with a purity of ≥ 99% (detected by HPLC), good solubility, soluble in polar solvents such as water, methanol, ethanol, etc., but poor solubility in non-polar solvents such as n-hexane and cyclohexane.

Mechanism of action and biological functions

The core mechanism of action of 5-Amino-1MQ is to selectively inhibit nicotinamide N-methyltransferase (NNMT), thereby regulating cellular energy metabolism and fat breakdown. NNMT is a key enzyme responsible for methylating nicotinamide (a form of vitamin B3) to 1-methylnicotinamide (1-MNA), which consumes S-adenosylmethionine (SAM) and affects the metabolic balance of NAD ⁺ (nicotinamide adenine dinucleotide). Inhibition of NNMT: 5-Amino-1MQ competitively binds to the active site of NNMT, blocking its catalytic reaction and leading to:
The increase in NAD ⁺ levels and the decrease in NNMT activity reduce the consumption of nicotinamide, making more nicotinamide available for NAD ⁺ synthesis, thereby increasing intracellular NAD ⁺ concentration. Enhanced energy metabolism, NAD ⁺ is a key coenzyme in the mitochondrial tricarboxylic acid cycle (TCA cycle) and oxidative phosphorylation. Elevated levels of NAD ⁺ can promote ATP production and increase cellular energy supply. Activation of fat breakdown, NNMT inhibition reduces the accumulation of white adipose tissue (WAT), while promoting the thermogenic activity of brown adipose tissue (BAT), accelerating fat breakdown.

Preparation process of 5-Amino-1MQ Capsule
Raw material preparation and quality control
Synthesis and Purification of 5-Amino-1MQ Raw Materials
The synthesis of 5-Amino-1MQ is usually achieved through chemical modification of quinoline derivatives. The following is a typical synthetic route:
Starting material
Starting from 5-nitroquinoline, amino groups are introduced through a reduction reaction.
Reaction conditions: In the presence of a catalyst (such as palladium on carbon), 5-nitroquinoline is reduced with hydrogen gas to produce 5-aminoquinoline.
Chemical equation:
![]()

Methylation reaction
5-Aminoquinoline is reacted with a methylation reagent (such as iodomethane) to produce the target product 5-Amino-1MQ.
Reaction conditions: Stir the reaction at room temperature for several hours in an organic solvent such as acetonitrile.
Chemical equation:
![]()

Purification and Crystallization: High purity 5-Amino-1MQ can be further purified by recrystallization (e.g. using ethanol water mixed solvent) or column chromatography (e.g. silica gel column).


Raw material quality control standards
Purity: ≥ 99% (HPLC detection, area normalization method).
Impurity restriction:
Residual solvents (such as acetonitrile, iodomethane) ≤ 0.1% (ICH guidelines).
Heavy metals (such as lead and cadmium) ≤ 10 ppm (ICP-MS detection).
Microbial limit: Total bacterial count ≤ 100 CFU/g, mold and yeast count ≤ 50 CFU/g.
Diluent filler
Microcrystalline cellulose (MCC): commonly used models are Avicel PH-101 or PH-102, providing good flowability and compressibility, and serving as a disintegrant to assist in capsule disintegration.
Lactose: Lactose monohydrate or anhydrous improves particle flowability, but attention should be paid to its suitability for lactose intolerant patients.
Lubricant
Magnesium stearate (MgSt): dosage 0.5% -1%, reduces friction between particles and dies, ensuring smooth compression.
Silicon dioxide (SiO ₂): used as a flow aid, with a dosage of 0.2% -0.5%, to improve powder flowability.


Disintegrator
Cross linked carboxymethyl cellulose sodium (CCNa): dosage of 2% -5%, accelerates capsule disintegration and promotes drug release.
Carboxymethyl starch sodium (CMS Na): replaces CCNa and provides a similar disintegration effect.
Coating material (optional)
Hydroxypropyl methylcellulose (HPMC): Used for film coating, improving appearance, masking odors, and controlling drug release rate.
Polyethylene glycol (PEG): used in combination with HPMC as a plasticizer to enhance the flexibility of the coating.
Preparation process flow
Wet granulation process (recommended)
Pre mixing: Mix the 5-Amino-1MQ raw material with some fillers (such as MCC) in proportion, pass through a 40 mesh sieve to ensure uniformity.
Granulation: Add adhesive solution (such as 5% HPMC ethanol solution) and stir in a high-speed mixing granulator for 2-3 minutes to form wet particles.
Drying: Place the wet particles in a fluidized bed dryer and dry at 40-50 ℃ until the moisture content is ≤ 3% (KF detection).
Whole granule: sieved through a 20 mesh sieve to remove large chunks or fine powder.
Total mixing: Add the remaining filler, disintegrant, and lubricant, mix for 10-15 minutes to ensure uniformity of content (RSD ≤ 5%).
Filling: Use a fully automatic capsule filling machine to fill the mixed powder into hard capsules (such as capsules 0 or 1), with a controlled filling volume difference of ≤± 5%.
Coating (optional): Film coating the capsule to control weight gain of 2% -4% and improve stability.
Adverse Reaction
The possible adverse reactions of 5-Amino-1MQ Capsule (if its core component is 5-aminosalicylic acid or its derivatives) are as follows:
Liver injury related reactions
Hepatocellular or mixed liver injury is a recurrent liver injury that may be caused by 5-aminosalicylate or its derivatives. Clinical manifestations include fever, rash, lymphadenopathy, lymphocytosis (absolute or relative), atypical lymphocytosis, and eosinophilia (a hypersensitivity reaction similar to infectious mononucleosis and serum diseases).
Liver biopsy shows inflammatory and necrotic changes in the liver, and in severe cases, large areas of necrosis may occur.Cholestasis jaundice has been reported to cause hepatocellular and cholestatic jaundice, characterized by symptoms such as jaundice, skin itching, and lighter stool color. The levels of aminotransferases (such as ALT and AST) may increase, usually occurring 1-8 weeks after medication, and a few patients may experience liver function abnormalities such as prolonged prothrombin time.
Gastrointestinal reactions
Gastrointestinal symptoms may include nausea, vomiting, abdominal pain, diarrhea, and other gastrointestinal symptoms caused by oral administration of 5-Amino-1MQ. These symptoms may be caused by direct stimulation of the gastric mucosa by drugs or inhibition of prostaglandin synthesis, leading to damage to the gastric mucosal barrier.
Reports have shown that taking 5-Amino-1MQ preparations may cause pancreatitis, manifested as upper abdominal pain, nausea, vomiting, and other symptom.
Allergic Reaction
Patients may experience skin allergic reactions such as rash, itching, and urticaria. These reactions usually occur within a few days to weeks after taking the medication, and in severe cases, severe allergic reactions such as exfoliative dermatitis may occur. Some patients may experience hypersensitivity reactions similar to infectious mononucleosis and serum diseases, manifested as fever, rash, lymphadenopathy, lymphocytosis, and other symptoms.
Hematological system reaction
5-Amino-1MQ may interfere with folate metabolism, leading to a decrease in white blood cells and symptoms such as fever and sore throat after secondary infection. Patients may experience abnormal bleeding or bruising, fatigue, weakness, shortness of breath, and other manifestations of thrombocytopenia or methemoglobinemia.
Hot Tags: 5-amino-1mq capsule, China 5-amino-1mq capsule manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, somatostatin tablets, glp1 shot, etelcalcetide structure

